Jean Jacques Bienaime - 14 Aug 2026 Form 4 Insider Report for Ascendis Pharma A/S (ASND)

Reporting relationship: Director
Issuer ticker: ASND
Reported as of: 14 Aug 2026
Net transaction value: +$492,654
SEC form: 4
Accepted by SEC: 18 Aug 2026, 21:02:43 UTC
Prior SEC filing: 17 Jul 2026
Next SEC filing: 19 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime

Key filing fact

Jean Jacques Bienaime filed Form 4 for Ascendis Pharma A/S (ASND) on 18 Aug 2026.

Key facts

This page summarizes Jean Jacques Bienaime's Form 4 filing for Ascendis Pharma A/S (ASND).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 21:02.

Change

Previous filing in this sequence was filed on 17 Jul 2026.
Current net transaction value: +$492,654.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001221590 Primary reporting owner

BIENAIME JEAN JACQUES

Relationship: Director
Address: C/O ASCENDIS PHARMA A/S, TUBORG BOULEVARD 12, HELLERUP, DENMARK
Signature: /s/ Michael Wolff Jensen as attorney-in-fact for Jean J Bienaime
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASND transaction

Ordinary Shares

Purchase

Transaction value: $270,435
Shares: +1,100
Change %: +122%
Price: $245.85
Shares after: 2,000
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1

ASND transaction

Ordinary Shares

Purchase

Transaction value: $222,219
Shares: +900
Change %: +45%
Price: $246.91
Shares after: 2,900
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $245.41 to $246.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $246.48 to $247.32 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.